Výsledky vyhledávání - "M. Apecechea"

Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy

Autor: M. Apecechea, S. Freytag, R. Ritter, R. Gmeinbauer, Manfred Windisch, E. Rüther

Publikováno v: Journal of neural transmission (Vienna, Austria : 1996). 107(7)

The present study is an extension of the work of Ruther et al. (1994). 101 patients suffering from DAT were evaluated 6 months after completion of a 4 week (5 days per week) therapy with either 30 ml Cerebrolysin or placebo. The significant and clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcf3bfa9653d27de46df8731e7e6d869
https://pubmed.ncbi.nlm.nih.gov/11005546

Zobrazit plný text záznamu

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)

Autor: Eckart Rüther, S. Freytag, R. Ritter, Manfred Windisch, M. Apecechea

Publikováno v: Pharmacopsychiatry. 27(1)

Cerebrolysin is a peptidergic nootropic drug with a multimodal mechanism of action. It is expected to have a positive influence on neurodegenerative diseases such as senile dementia of the Alzheimer type (SDAT). Experimental studies have shown Cerebr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93548b4e52f412ca09bab2a28cd04c36
https://pubmed.ncbi.nlm.nih.gov/8159781

Zobrazit plný text záznamu

Efficacy of Cerebrolysin® in Alzheimer’s disease

Autor: R. Ritter, Manfred Windisch, E. Ruether, M. Apecechea, S. Freitag

Publikováno v: New Trends in the Diagnosis and Therapy of Alzheimer’s Disease ISBN: 9783211826201

Background. Alzheimer’s disease (AD) accounts for about half of all cases of senile dementia. Its prevelance increases steeply with age, from less than 1% at 60 to 15% in the 9th decade. The disease causes great suffering to patients and their fami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f637cc42bdd666952e9b8fe22b60160
https://doi.org/10.1007/978-3-7091-9376-1_10

Zobrazit plný text záznamu

Therapeutic Results with Nimodipine in Primary Degenerative Dementia and Multi-Infarct Dementia

Autor: P. K. Fischhof, G. Wagner, N. Schmage, F. Hoffmeister, L. Littschauer, R. Hiersemenzel, M. Apecechea, J. Röhmel, E. Rüther

Publikováno v: Diagnosis and Treatment of Senile Dementia ISBN: 9783540508007

The diagnostic label of dementia is not justified in all elderly patients with cognitive decline. However, an organic factor of unknown aetiology can also be assumed in patients suffering from a milder decline. Therefore, the term “organic brain sy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c37d33511720eb7f52c8169cc6bea323
https://doi.org/10.1007/978-3-642-46658-8_27

Zobrazit plný text záznamu

Tolerance and pharmacokinetics of oral fendiline

Autor: R, Weyhenmeyer, E, Fenzl, M, Apecechea, K D, Rehm, C J, Dyde, K J, Johnson, R, Friedel

Publikováno v: Arzneimittel-Forschung. 37(1)

Two studies with healthy volunteers were carried out to correlate safety with pharmacokinetics of the calcium antagonistic drug N-(3,3-diphenylpropyl)-(1-phenylethyl)-amine (fendiline, Sensit) after single and multiple oral doses. In the first study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::132e5f55fa1f599be433f692d721dd1c
https://pubmed.ncbi.nlm.nih.gov/3566858

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání